News
KMDA
5.06
-0.39%
-0.02
Weekly Report: what happened at KMDA last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at KMDA last week (0401-0405)?
Weekly Report · 04/08 09:13
Weekly Report: what happened at KMDA last week (0325-0329)?
Weekly Report · 04/01 09:12
Weekly Report: what happened at KMDA last week (0318-0322)?
Weekly Report · 03/25 09:12
Weekly Report: what happened at KMDA last week (0311-0315)?
Weekly Report · 03/18 09:12
Weekly Report: what happened at KMDA last week (0304-0308)?
Weekly Report · 03/11 09:12
HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target
Benzinga · 03/07 12:35
Strategic Partnerships and Product Portfolio Expansion Poise Kamada for Robust Growth
TipRanks · 03/07 11:26
KMDA Stock Earnings: Kamada Beats EPS, Misses Revenue for Q4 2023
Kamada reported earnings per share of 9 cents. The company reported revenue of $36.43 million. Kamada's revenue was 3.39% worse than the analyst estimate of $37.71 million for the quarter. The stock is down 2.7% today.
Investorplace · 03/06 17:52
Kamada Expects 2024 Revenues Of $156M-$160M Vs. $166.14M Consensus, And Sees Adjusted EBITDA In The Range Of $27M-$30M
Kamada expects to generate fiscal year 2024 total revenues in the range of $156 million to $160 million. The company expects double digit top- and bottom-line growth through 2024. Full-year 2024 revenue guidance for Kamada is $156m-$160m and adjusted EBITDA of $27m-$30m.
Benzinga · 03/06 12:07
Kamada GAAP EPS of $0.15, revenue of $142.51M
Kamada Ltd. Reports Q4 GAAP EPS of $0.15, revenue of $142.51M (+10.2% Y/Y). The increase in revenues was primarily attributable to increased sales of KEDRAB to Kedrion.
Seeking Alpha · 03/06 12:05
Kamada Q4 EPS $0.09 Beats $0.05 Estimate, Sales $36.43M Miss $37.71M Estimate
Kamada reported quarterly earnings of $0.09 per share. The company reported quarterly sales of $36.43 million. Kamada beat the analyst consensus estimate of $1.02 per share by 80%. The company's sales for the quarter were down 19.82 percent from the same period last year.
Benzinga · 03/06 12:03
Earnings Scheduled For March 6, 2024
Foot Locker is likely to report quarterly earnings at $0.32 per share on revenue of $2.28 billion. JD.com is expected to report earnings for its fourth quarter. CTS is estimated to report its quarterly earnings before the bell. Other companies reporting before the Bell include Campbell Soup, Super Group and Abercrombie & Fitch.
Benzinga · 03/06 10:00
Kamada: Q4 Earnings Snapshot
Kamada Ltd. Reported net income of $5.1 million in its fourth quarter. The biopharmaceutical posted revenue of $36.4 million in the period. For the year, the company reported profit of $8.3 million. Kamada expects full-year revenue in the range of $156 million to $160 million.
Barchart · 03/06 06:35
Kamada Issues 2024 CEO Letter to Shareholders
Kamada Ltd. Is a leader in the specialty plasma-derived field. The company has a portfolio of marketed products indicated for rare and serious conditions. Kamada is a commercial stage global biopharmaceutical company. The letter to shareholders is from Amir London, Chief Executive Officer.
Barchart · 03/06 06:05
Preview: Kamada's Earnings
Kamada is set to give its latest quarterly earnings report on Wednesday, 2024-03-06. Analysts estimate the company will report an earnings per share of $0.05. Shares of Kamada were trading at $6.39 as of March 04.
Benzinga · 03/05 19:02
Weekly Report: what happened at KMDA last week (0226-0301)?
Weekly Report · 03/04 09:12
Weekly Report: what happened at KMDA last week (0219-0223)?
Weekly Report · 02/26 09:14
Weekly Report: what happened at KMDA last week (0212-0216)?
Weekly Report · 02/19 09:14
Weekly Report: what happened at KMDA last week (0205-0209)?
Weekly Report · 02/12 09:13
More
Webull provides a variety of real-time KMDA stock news. You can receive the latest news about Kamada Ltd through multiple platforms. This information may help you make smarter investment decisions.
About KMDA
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.